Kevin Flanigan
Professor of Pediatrics and Neurology
Ohio State University College of Medicine
Position in Extended Committee - Clinical Representative
Kevin is the Director of the United Dystrophinopathy Project, an NIH-funded consortium studying the natural history and genotype/phenotype correlations in the DMD gene. He has participated in several recent clinical treatment trials, including use of MYO-029 (Wyeth, Inc.), IPLEX (Insmed, Inc.), and PTC124 (both 2a and 2b studies; PTC, Inc.). He has served on expert advisory committees for developing clinical protocols for exon skipping therapies, and for other therapies in pre-clinical development.
